Delpor’s Implant Device
We are delighted to announce that Delpor is the latest company to join the Kairos portfolio, following our investment in their recent bridge round.
Based in San Francisco, CA, Delpor is developing innovative drug delivery implant technologies in order to create long-acting pharmaceutical formulations. These new therapeutic products are expected to provide substantial clinical benefits including improved medication adherence, safety and efficacy, as well as patient convenience when frequent injections are required.
“As an entrepreneur, I like working with other entrepreneurs. The Kairos team is a group of entrepreneurs, who also happen to be investors. From the very beginning, they have shown a genuine interest in our company, and have acted as an extension of our founder team.”
– Tassos Nicolaou, co-founder and CEO of Delpor
“What attracted us to Delpor is their unique approach of deep research combined with pragmatic, deliberate, commercial development efforts,” says Jim Jeffs, who will be joining the Delpor Board as an observer.
Delpor’s high-performance Drug Delivery System will be used with patients suffering from chronic conditions, with an initial focus on delivering a solution for patients taking antipsychotic medications for schizophrenia maintenance therapy. We are delighted to be playing a small role in helping improve the lives of those suffering from such devastating conditions.
“As an entrepreneur, I like working with other entrepreneurs,” says Tassos Nicolaou, co-founder and CEO of Delpor and a Stanford graduate. “The Kairos team is a group of entrepreneurs, who also happen to be investors. From the very beginning, they have shown a genuine interest in our company, and have acted as an extension of our founder team.”
We are very excited about our investment in Delpor and would like to welcome them to the extended Kairos Ventures family.
